1 CDC Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR. 1989;38:1–9.
2 Thomas CF, Limper AH. Pneumocystis Pneumonia. New England Journal of Medicine. 2004;350:2487–98.
3 Hof H. Pneumocystis jirovecii: a peculiar fungus posing particular problems for therapy and prophylaxis. Mycoses. 2012;55:1–7.
4 Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis jiroveci pneumonia in non-HIV immunocomprismised patients. 2015. Cochrane Database Sys Review.
5 Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii Pneumonia in patients with or without AIDS, France. Emerging Infectious Diseases. 2014;9:1490–6.
6 Salzer HJF, Schafer G, Hoenigl M, Gunther G, Hoffman C, Kalsdorf B, et al. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia. Respiration. 2018;96(1):52–65.
7 Chatelanat O, Van Delden C, Adler D, Guerne PA, Nendaz M, Serratrice J. Facteurs de risque et prophylaxie de la pneumonie à Pneumocystis jirovecii chez les patients non VIH. Rev Med Suisse. 2018;14:1829–33.
8 Avino L, Naylor S, Roecker A. Pneumocystis jiroveci Pneumonia in the non-HIV-Infected Population. Annals of Pharmacology. 2016;50(8):673–79.
9 Lu Y, Ling G, Ying Z. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol. 2011;49(12):4361–3.
10 Kumagai S, Arita M, Koyama T, Inoue D, Nakagawa A, Kaji Y, et al. Prognostic significance of crazy paving ground glass opacities in non-HIV Pneumocystis jirovecii pneumonia: an observational cohort study. BMC Pulm Med. 2019;19:47.
11 Matsumura Y, Shindo Y, Iinuma Y, Yamamato M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infectious Diseases. 2011,11:76.
12 Rogina P, Skvarc M. Diagnostic Accuracy of (1-3)-beta-glucan to Predict Pneumocystis Jirovecii Pneumonia in non-HIV-infected Patients. Radiology and Oncology. 2020;54(2):221–6.
13 Lee HY, Kang HS, Kang JY. Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice. Korean J Intern Med. 2017;32:478–85.
14 Tapparel L, Petignat PA, Praz G. Diagnostique de la pneumonie a Pneumocystis jiroveci chez le patient non VIH. Revue Med Suisse. 2010;6:1922–5.
15 Baden LR, Swaminathan S, Angarone M, Blouin G, Camins B, Casper C. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2016;14(7):882–913.
16 Barreto JN, Ice LL, Thompson CA, Tosh PK, Osmon DR, Dierkhising RA, et al. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. Am J Hematol. 2016;91(11):1113–7.
17 Fishman JA, Gans H. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation. 2019;33(9):e13587.
18 Sibanda EL, Weller I, Hakim JG, Cowan FM. Does Trimethoprim-Sulfamethoxazole Prophylaxis for HIV Induce Bacterial Resistance to Other Antibiotic Classes?: Results of a Systematic Review. Clinical Infectious Diseases. 2011;52(9):1184–94.
19 Martin SI, Fishman JA. Pneumocystis Pneumonia in Solid Organ Transplantation. American Journal of Transplantation. 2013;13(s4):272–9.
20 Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal. 2014;44(12b):1350–63.
21 Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infection and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013;92:433–42.